By
Drug Target Review2024-08-12T16:00:43
Increased gene activity in the SYK pathway could be the basis of a blood test to identify melanoma patients most susceptible to severe side effects.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2023-12-11T10:49:07
Sponsored by Leica Microsystems
2026-05-22T07:38:00
Contributor Dr Helen Bright, By Drug Target Review
2023-05-18T10:39:07
Sponsored by BPS Bioscience
2023-05-23T11:10:47
Sponsored by NanoTemper Technologies
2025-10-08T14:00:00
Sponsored by Eurofins Discovery
2025-05-14T14:30:00
Sponsored by Abzena
Site powered by Webvision Cloud